CATHERINE MOSS: Open Payments
NPI 1841329166 · NORTH KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$315 in 10 payments from 7 companies in 2025. Trend: 2023 $590 · 2024 $272 · 2025 $315
Food & beverage: $315
| Company | Payments | Amount |
|---|---|---|
| AKEBIA THERAPEUTICS INC | 1 | $108 |
| Novartis Pharmaceuticals Corporation | 2 | $60 |
| Calliditas Therapeutics US Inc. | 2 | $57 |
| GlaxoSmithKline, LLC. | 1 | $27 |
| Travere Therapeutics, Inc. | 2 | $23 |
| Novo Nordisk Inc | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
Products named: Vafseo, Vanrafia, TARPEYO, BENLYSTA, Ozempic, FARXIGA.
Industry payments across MO — which companies pay providers there.
